EGF and malignant colon neoplasm: Interestingly, in EGF-treated colon cancer cells, the HT-cetuximab combination challenge caused a significant increase in the sub G0/G1 population (Figure 4A and 4B, grey bars and Supplementary Tables 1 and 2), which was accompanied by accumulation of cells at G2/M- and by a decrease in those in S-phase (Figure 4A and 4B, black and dark grey bars, respectively, and Supplementary Tables 1 and 2).